Clinical Trial

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 23, 2025 (before its estimated June 26, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a 2-Stage, Phase I/II Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-11-06; most recent amendment 2025-12-16.
Status change: Not Yet Recruiting → Recruiting 2025-03-14
Trial Details
NCT Number NCT06680128
Lead Sponsor SK Bioscience Co., Ltd.
Conditions Japanese Encephalitis Virus Disease
Enrollment 402 participants
Start Date 2025-02-24
Primary Completion 2026-06-26 (estimated)
Study Completion 2028-03-19 (estimated)
Updated on ClinicalTrials.gov 2025-12-23